Cargando…
A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID)
BACKGROUND: COVID-19 has quickly become a global pandemic with a substantial number of deaths and is a considerable burden for healthcare systems worldwide. Although most cases are paucisymptomatic and limited to the viral infection-related symptoms, some patients evolve to a second phase, with an i...
Autores principales: | Malchair, Pierre, Otero, Aurema, Giol, Jordi, Solanich, Xavier, Carnaval, Thiago, Fernández-Nistal, Alonso, Sánchez-Gabriel, Ana, Montoto, Carmen, Lleonart, Ramon, Videla, Sebastián |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9003174/ https://www.ncbi.nlm.nih.gov/pubmed/35413921 http://dx.doi.org/10.1186/s13063-022-06219-7 |
Ejemplares similares
-
Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial
por: Malchair, Pierre, et al.
Publicado: (2023) -
87 Treatment of Idiopathic Nonhistaminergic Angiodema with Icatibant
por: Lleonart, Ramon, et al.
Publicado: (2012) -
Postoperative complications and mortality following emergency digestive surgery during the COVID-19 pandemic: A multicenter collaborative retrospective cohort study protocol (COVID-CIR)
por: Madrazo, Zoilo, et al.
Publicado: (2021) -
Suspected adverse events following immunization against SARS-CoV2 in a university hospital in 2021: Observational study
por: Rodríguez, Dolores, et al.
Publicado: (2022) -
Hereditary angioedema: epidemiology, management, and role of icatibant
por: Ghazi, Aasia, et al.
Publicado: (2013)